Clinical Trials Logo

Advanced Prostate Adenocarcinoma clinical trials

View clinical trials related to Advanced Prostate Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06173362 Recruiting - Clinical trials for Stage IV Prostate Cancer AJCC v8

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Start date: November 9, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Androgens (male hormones) can cause the growth of prostate tumor cells. Abiraterone acetate lowers the amount of androgens made by the body. This may help stop the growth of prostate tumor cells that need androgen to grow. Darolutamide blocks the use of androgens by the tumor cells. Prednisone is used to lessen inflammation and lower the body's immune response. Researchers want to compare the side effects of standard of care (SOC) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.

NCT ID: NCT04914195 Completed - Clinical trials for Advanced Prostate Adenocarcinoma

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

This is a Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 clinical study to compare the efficacy, safety, and pharmacokinetics of leuprolide acetate for injection 3.75mg (depot) of two brands (Luprodex and Lucrin) administered in subjects with advanced adenocarcinoma of the prostate. Approximately 168 subjects (males )of age above 18 years fulfilling the eligibility criteria will be enrolled. The IP will be given as a monthly dose for two cycles on day 0 and day 28. The pharmacokinetic analysis will be done for 12 patients receiving Luprodex. The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.

NCT ID: NCT04843319 Terminated - Clinical trials for Advanced Prostate Adenocarcinoma

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

VERU-100
Start date: June 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.

NCT ID: NCT00502164 Completed - Clinical trials for Advanced Prostate Adenocarcinoma

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

AZD2171IL/0003
Start date: March 2004
Phase: Phase 1
Study type: Interventional

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.